Objectives: In recent years, it has been possible to preserve hearing after cochlear implantation in patients with significant amounts of low-frequency residual hearing. Due to the dimensions and characteristics of the cochlear implants (CIs) Nucleus® Hybrid™-L24 and Nucleus Freedom™ CI422, both can be used to preserve residual hearing. The aim was to investigate the degree and progression of hearing preservation over a longitudinal postoperative period in a large consecutive cohort of implanted patients with preoperative residual hearing who received either the Nucleus Hybrid-L24 or the Nucleus Freedom CI422 implant. The intention was to examine potential characteristics and triggers of resulting postoperative hearing loss which may support a differentiation of CI candidacy criteria for a certain implant type. Methods: A retrospective data analysis of patient files on consecutively implanted subjects presenting with a severe-to-profound sensorineural hearing loss at frequencies >1,500 Hz and substantial residual hearing at frequencies ≤1,500 Hz, implanted with a Nucleus Hybrid-L24 (n = 97) or a CI422 implant (n = 100), was undertaken. A single-subject repeated-measure design comparing the mean threshold shift for pure-tone thresholds under headphones up to 24 months after implantation was used. Results: Hearing preservation is observed in the majority of subjects with either implant (250-1,500 Hz frequency range). Hybrid-L24 patients exhibited a median hearing loss of 10 dB at initial fitting (n = 97) and of 15 dB after 24 months (n = 51). A 14.4-dB decrease in median hearing loss at initial fitting (n = 100) and a 30-dB decrease after 24 months (n = 28) was observed with the CI422 electrode. At initial fitting, 54.6% of the Hybrid-L24 (n = 97) and 49.0% of the CI422 (n = 100) subjects showed a mean threshold shift <15 dB. After 24 months, 58.8% (Hybrid-L24, n = 51) and 28.6% (CI422, n = 28) of the patients showed a mean threshold shift <15 dB. Conclusions: The results indicate that residual hearing was preserved for the majority of implanted patients with the Hybrid-L24 and the CI422 implant. Patients implanted with the Hybrid-L24 implant demonstrate greater stability and less median hearing loss over time than those with the CI422 implant. Assessments of onset and stability of hearing loss prior to implantation are important factors to consider during candidacy evaluation for electrode selection to potentially maximize the performance outcome for each patient.

Keywords:
Cochlear implant, Residual hearing, Hearing preservation, Nucleus® Freedom™ CI422, Nucleus Hybrid™-L24
1.
Büchner A, Schüssler M, Battmer RD, Stöver T, Lesinski-Schiedat A, Lenarz T: Impact of low-frequency hearing. Audiol Neurotol 2009;14(suppl 1):8-13.
2.
Erixon E, Kobler S, Rask-Andersen H: Cochlear implantation and hearing preservation: results in 21 consecutively operated patients using the round window approach. Acta Otolaryngol 2012;132:923-931.
3.
Fayad JN, Linthicum FH Jr: Multichannel cochlear implants: relation of histopathology to performance. Laryngoscope 2006;116:1310-1320.
4.
Fayad JN, Makarem AO, Linthicum FH Jr: Histopathologic assessment of fibrosis and new bone formation in implanted human temporal bones using 3D reconstruction. Otolaryngol Head Neck Surg 2009;141:247-252.
5.
Gantz BJ, Hansen MR, Turner CW, Oleson JJ, Reiss LA, Parkinson AJ: Hybrid 10 clinical trial: preliminary results. Audiol Neurotol 2009;14(suppl 1):32-38.
6.
Gantz BJ, Turner CW: Combining acoustic and electrical hearing. Laryngoscope 2003;113:1726-1730.
7.
Gantz BJ, Turner C, Gfeller KE: Acoustic plus electric speech processing: preliminary results of a multicenter clinical trial of the Iowa/Nucleus Hybrid implant. Audiol Neurotol 2006;11(suppl 1):63-68.
8.
Gstöttner W, Helbig S, Settevendemie C, Baumann U, Wagenblast J, Arnoldner C: A new electrode for residual hearing preservation in cochlear implantation: first clinical results. Acta Otolaryngol 2009;129:372-379.
9.
Gstöttner W, Pok SM, Peters S, Kiefer J, Adunka O: Cochlear implantation with preservation of residual deep frequency hearing (in German). HNO 2005;53:784-790.
10.
James C, Albegger K, Battmer R, Burdo S, Deggouj N, Deguine O, Dillier N, Gersdorff M, Laszig R, Lenarz T, Rodriguez MM, Mondain M, Offeciers E, Macias AR, Ramsden R, Sterkers O, Von Wallenberg E, Weber B, Fraysse B: Preservation of residual hearing with cochlear implantation: how and why. Acta Otolaryngol 2005;125:481-491.
11.
Kurzweg T, Dalchow CV, Bremke M, Majdani O, Kureck I, Knecht R, Werner JA, Teymoortash A: The value of digital volume tomography in assessing the position of cochlear implant arrays in temporal bone specimens. Ear Hear 2010;31:413-419.
12.
Lenarz T, Stöver T, Büchner A, Lesinski-Schiedat A, Patrick J, Pesch J: Hearing conservation surgery using the Hybrid-L electrode. Results from the first clinical trial at the Medical University of Hannover. Audiol Neurotol 2009;14(suppl 1):22-31.
13.
Lenarz T, Stöver T, Büchner A, Paasche G, Briggs R, Risi F, Pesch J, Battmer RD: Temporal bone results and hearing preservation with a new straight electrode. Audiol Neurotol 2006;11(suppl 1):34-41.
14.
Mukherjee P, Uzun-Coruhlu H, Wong CC, Curthoys IS, Jones AS, Gibson WP: Assessment of intracochlear trauma caused by the insertion of a new straight research array. Cochlear Implants Int 2012;13:156-162.
15.
Peyvandi A, Naghibzadeh B, Ahmady Roozbahany N: Neuro-otologic manifestations of multiple sclerosis. Arch Iran Med 2010;13:188-192.
16.
Skarzynski H, Lorens A, Matusiak M, Porowski M, Skarzynski PH, James CJ: Partial deafness treatment with the nucleus straight research array cochlear implant. Audiol Neurotol 2012;17:82-91.
17.
Skarzynski H, Podskarbi-Fayette R: A new cochlear implant electrode design for preservation of residual hearing: a temporal bone study. Acta Otolaryngol 2010;130:435-442.
18.
Turner C, Gantz BJ, Reiss L: Integration of acoustic and electrical hearing. J Rehabil Res Dev 2008;45:769-778.
19.
von Ilberg C, Kiefer J, Tillein J, Pfenningdorff T, Hartmann R, Stürzebecher E, Klinke R: Electric-acoustic stimulation of the auditory system. New technology for severe hearing loss. ORL J Otorhinolaryngol Relat Spec 1999;61:334-340.
20.
Woodson EA, Reiss LA, Turner CW, Gfeller K, Gantz BJ: The Hybrid cochlear implant: a review. Adv Otorhinolaryngol 2010;67:125-134.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.